TY - JOUR
T1 - Hereditary angioedema
T2 - Validation of the end point time to onset of relief by correlation with symptom intensity
AU - Bernstein, Jonathan A.
AU - Ritchie, Bruce
AU - Levy, Robyn J.
AU - Wasserman, Richard L.
AU - Bewtra, Againdra K.
AU - Hurewitz, David S.
AU - Obtułowicz, Krystyna
AU - Reshef, Avner
AU - Moldovan, Dumitru
AU - Shirov, Todor
AU - Grivcheva-Panovska, Vesna
AU - Kiessling, Peter C.
AU - Keinecke, Heinz Otto
AU - Craig, Timothy J.
PY - 2011/1
Y1 - 2011/1
N2 - Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.
AB - Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.
UR - http://www.scopus.com/inward/record.url?scp=79551490988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551490988&partnerID=8YFLogxK
U2 - 10.2500/aap.2011.32.3404
DO - 10.2500/aap.2011.32.3404
M3 - Article
C2 - 21262096
AN - SCOPUS:79551490988
SN - 1088-5412
VL - 32
SP - 36
EP - 42
JO - Allergy and Asthma Proceedings
JF - Allergy and Asthma Proceedings
IS - 1
ER -
